Moreover, early adaptation of ER+ breast cancer cell models to CDK4/6i has been associated with increased activity of CDK2 by noncanonical binding with cyclin D1 mediating G1/S transition cell cycle entry [12]. Here, CDK4 is linked to breast cancer.